Merck用100亿美元购买Verona Pharma, 以获得其COPD药物,Ohtuvare。 Merck buys Verona Pharma for $10 billion to acquire its COPD drug, Ohtuvayre.

Merck同意以约100亿美元购买Verona Pharma, 以获得其抗逆转录病毒药物Ohtuvaayre。 Merck has agreed to acquire Verona Pharma for about $10 billion to gain access to its COPD medication, Ohtuvayre. 2024年6月经林业发展局批准,Ohtuvayre治疗成人慢性阻塞性肺病。 Approved by the FDA in June 2024, Ohtuvayre treats chronic obstructive pulmonary disease in adults. 这笔交易旨在使Merck的投资组合多样化,因为其顶级销售的癌症药物Keytruda在2028年面临专利到期。 The deal aims to diversify Merck's portfolio as its top-selling cancer drug, Keytruda, faces patent expiration in 2028. 收购预计将在第四季度结束,但须经股东和监管部门批准。 The acquisition is expected to close in the fourth quarter, subject to shareholder and regulatory approvals.